Towards biomarker-based tests that can facilitate decisions about prevention and management of preeclampsia in low-resource settings

Clinical Chemistry and Laboratory Medicine

Volumn 54, Issue 1, 2016, Pages 17-27

  Acestor, Nathalie ^a   Goett, Jane ^a   Lee, Arthur ^a   Herrick, Tara M ^a   Engelbrecht, Susheela M ^a   Harner Jay, Claudia M ^a   Howell, Bonnie J ^b   Weigl, Bernhard H ^a  

^a PATH   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

biomarkers; low resource settings; point of care; preeclampsia; rapid diagnostic test

Indexed keywords

ALPHA ENOLASE; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; CA 125 ANTIGEN; CALCYCLIN; COMPLEMENT COMPONENT C5B; COMPLEMENT FACTOR D; COPEPTIN; ENDOGLIN; FIBRONECTIN; GALECTIN 1; GLUCOSE REGULATED PROTEIN 78; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INOSITOL; IODINE; KIDNEY INJURY MOLECULE 1; MALONALDEHYDE; MARINOBUFAGENIN; N(G),N(G) DIMETHYLARGININE; NEPHRIN; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; PENTRAXIN 3; PLACENTAL GROWTH FACTOR; PREALBUMIN; PROLACTIN; STEM CELL FACTOR RECEPTOR; URIC ACID; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASOPRESSIN;

AREA UNDER THE CURVE; ARTICLE; DIASTOLIC BLOOD PRESSURE; FEMALE; GESTATIONAL AGE; HUMAN; META ANALYSIS; POINT OF CARE TESTING; PREDICTIVE VALUE; PREECLAMPSIA; PRIORITY JOURNAL; PROTEINURIA; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; URIC ACID BLOOD LEVEL; BLOOD; HEALTH CARE PLANNING; METABOLISM; PRE-ECLAMPSIA; PREGNANCY; URINE;

BIOMARKERS; FEMALE; HEALTH RESOURCES; HUMANS; POINT-OF-CARE TESTING; PRE-ECLAMPSIA; PREGNANCY;

EID: 84954349016     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2015-0069     Document Type: Article

References (70)

1. Duley L. The global impact of pre-eclampsia and eclampsia. Semin Perinatol 2009;33:130-7.
2. Khan KS, Wojdyla D, Say L, Gülmezoglu AM, Van Look PF. WHO analysis of causes of maternal death: A systematic review. Lancet 2006;367:1066-74.
3. Payne BA, Hutcheon JA, Ansermino JM, Hall DR, Bhutta ZA, Bhutta SZ, et al. A risk prediction model for the assessment and triage of women with hypertensive disorders of pregnancy in low-resourced settings: The miniPIERS (Pre-eclampsia Integrated Estimate of RiSk) multi-country prospective cohort study. PLoS Med 2014;11:e1001589.
4. English FA, Kenny LC, McCarthy FP. Risk factors and effective management of preeclampsia. Integr Blood Press Control 2015;8:7-12.
5. Gizzo S, Patrelli TS, Rossanese M, Noventa M, Berretta R, Di Gangi S, et al. An update on diabetic women obstetrical outcomes linked to preconception and pregnancy glycemic profile: A systematic literature review. Sci World J 2013;2013:254901.
6. Yuster EA. Rethinking the role of the risk approach and antenatal care in maternal mortality reduction. Int J Gynecol Obstet 1995;50(Suppl 2):S59-61.
7. Fortney JA. Antenatal risk screening and scoring: A new look. Int J Gynecol Obstet 1995;50(Suppl 2):S53-8.
8. Menzies J, Magee LA, Macnab YC, Ansermino JM, Li J, Douglas MJ. Current CHS and NHBPEP criteria for severe preeclampsia do not uniformly predict adverse maternal or perinatal outcomes. Hypertens Pregnancy 2007;26:447-62.
9. Brown MA. Pre-eclampsia: proteinuria in pre-eclampsia-does it matter any more? Nat Rev Nephrol 2012;8:563-5.
10. Park JH, Chung D, Cho HY, Kim YH, Son GH, Park YW, et al. Random urine protein/creatinine ratio readily predicts proteinuria in preeclampsia. Obstet Gynecol Sci 2013;56:8-14.
11. Côté AM, Brown MA, Lam E, von Dadelszen P, Firoz T, Liston RM, et al. Diagnostic accuracy of urinary spot protein:creatinine ratio for proteinuria in hypertensive pregnant women: systematic review. Br Med J 2008;336:1003-6.
12. Thornton CE, Makris A, Ogle RF, Tooher JM, Hennessy A. Role of proteinuria in defining pre-eclampsia: clinical outcomes for women and babies. Clin Exp Pharmacol Physiol 2010;37:466-70.
13. Sibai BM, Stella CL. Diagnosis and management of atypical preeclampsia-eclampsia. Am J Obstet Gynecol 2009;200:481. e1-7.
14. Kharb S. Serum markers in pre-eclampsia. Biomarkers 2009;14:395-400.
15. Carty DM, Delles C, Dominiczak AF. Novel biomarkers for predicting preeclampsia. Trends Cardiovasc Med 2008;18:186-94.
16. Anderson UD, Olsson MG, Kristensen KH, Akerström B, Hansson SR. Review: biochemical markers to predict preeclampsia. Placenta 2012;33(Suppl):S42-7.
17. Masoura S, Kalogiannidis IA, Gitas G, Goutsioulis A, Koiou E, Athanasiadis A, et al. Biomarkers in pre-eclampsia: A novel approach to early detection of the disease. J Obstet Gynaecol 2012;32:609-16.
18. Warrington JP, George EM, Palei AC, Spradley FT, Granger JP. Recent advances in the understanding of the pathophysiology of preeclampsia. Hypertension 2013;62:666-73.
19. Benton SJ, Hu Y, Xie F, Kupfer K, Lee SW, Magee LA, et al. Angiogenic factors as diagnostic tests for preeclampsia: A performance comparison between two commercial immunoassays. Am J Obstet Gynecol 2011;205:469.e1-8.
20. Thiam S, Thior M, Faye B, Ndiop M, Diouf ML, Diouf MB, et al. Major reduction in anti-malarial drug consumption in Senegal after nation-wide introduction of malaria rapid diagnostic tests. PLoS One 2011;6:e18419.
21. Parekh BS, Kalou MB, Alemnji G, Ou CY, Gershy-Damet GM, Nkengasong JN. Scaling up HIV rapid testing in developing countries: comprehensive approach for implementing quality assurance. Am J Clin Pathol 2010;134:573-84.
22. Pollock NR, McGray S, Colby DJ, Noubary F, Nguyen H, Nguyen TA. Field evaluation of a prototype paper-based pointof-care fingerstick transaminase test. PLoS One 2013;8:e75616.
23. Lochhead MJ, Todorof K, Delaney M, Ives JT, Greef C, Moll K, et al. Rapid multiplexed immunoassay for simultaneous serodiagnosis of HIV-1 and coinfections. J Clin Microbiol 2011;49:3584-90.
24. World Health Organization. WHO managing complications in pregnancy and childbirth: A guide for midwives and doctors. Available from: http://whqlibdoc.who.int/publications/ 2007/9241545879-eng.pdf?ua=1. Accessed on 16 December, 2014.
25. Rana S, Cerdeira AS, Wenger J, Salahuddin S, Lim KH, Ralston SJ, et al. Plasma concentrations of soluble endoglin versus standard evaluation in patients with suspected preeclampsia. PLoS One 2012;7:e48259.
26. Chen G, Zhang L, Jin X, Zhou Y, Niu J, Chen J, et al. Effects of angiogenic factors, antagonists, and podocyte injury on development of proteinuria in preeclampsia. Reprod Sci 2013;20:579-88.
27. Salahuddin S, Lee Y, Vadnais M, Sachs BP, Karumanchi SA, Lim KH. Diagnostic utility of soluble fms-like tyrosine kinase 1 and soluble endoglin in hypertensive diseases of pregnancy. Am J Obstet Gynecol 2007;197:28.e1-6.
28. Buhimschi CS, Baumbusch MA, Dulay AT, Lee S, Wehrum M, Zhao G, et al. The role of urinary soluble endoglin in the diagnosis of pre-eclampsia: comparison with soluble fms-like tyrosine kinase 1 to placental growth factor ratio. Br J Obstet Gynaecol 2010;117:321-30.
29. Ohkuchi A, Hirashima C, Suzuki H, Takahashi K, Yoshida M, Matsubara S, et al. Evaluation of a new and automated electrochemiluminescence immunoassay for plasma sFlt-1 and PlGF levels in women with preeclampsia. Hypertens Res 2010;33:422-7.
30. Muy-Rivera M, Vadachkoria S, Woelk GB, Qiu C, Mahomed K, Williams MA. Maternal plasma VEGF, sVEGF-R1, and PlGF concentrations in preeclamptic and normotensive pregnant Zimbabwean women. Physiol Res 2005;54:611-22.
31. Siddiqui AH, Irani RA, Blackwell SC, Ramin SM, Kellems RE, Xia Y. Angiotensin receptor agonistic autoantibody is highly prevalent in preeclampsia: correlation with disease severity. Hypertension 2010;55:386-93.
32. Ozat M, Kanat-Pektas M, Yenicesu O, Gungor T, Danisman N, Mollamahmutoglu L. Serum concentrations of CA-125 in normal and preeclamptic pregnancies. Arch Gynecol Obstet 2011;284:607-12.
33. Burwick RM, Fichorova RN, Dawood HY, Yamamoto HS, Feinberg BB. Urinary excretion of C5b-9 in severe preeclampsia: tipping the balance of complement activation in pregnancy. Hypertension 2013;62:1040-5.
34. Zulfikaroglu E, Islimye M, Tonguc EA, Payasli A, Isman F, Var T, et al. Circulating levels of copeptin, a novel biomarker in preeclampsia. J Obstet Gynaecol Res 2011;37:1198-202.
35. Laverriere A, Landau R, Charvet I, Irion O, Bischof P, Morales M. GRP78 as a marker of pre-eclampsia: an exploratory study. Mol Hum Reprod 2009;15:569-74.
36. Freitag N, Tirado-Gonzalez I, Barrientos G, Herse F, Thijssen VL, Weedon-Fekjar SM, et al. Interfering with Gal-1-mediated angiogenesis contributes to the pathogenesis of preeclampsia. Proc Natl Acad Sci USA 2013;110:11451-6.
37. Stepan H, Richter J, Kley K, Kralisch S, Jank A, Schaarschmidt W, et al. Serum levels of growth arrest specific protein 6 are increased in preeclampsia. Regul Pept 2013;182:7-11.
38. Rolfo A, Many A, Racano A, Tal R, Tagliaferro A, Ietta F, et al. Abnormalities in oxygen sensing define early and late onset preeclampsia as distinct pathologies. PLoS One 2010;5:e13288.
39. Ishibashi O, Ohkuchi A, Ali MM, Kurashina R, Luo SS, Ishikawa T, et al. Hydroxysteroid (17) dehydrogenase 1 is dysregulated by miR-210 and miR-518c that are aberrantly expressed in preeclamptic placentas: A novel marker for predicting preeclampsia. Hypertension 2012;59:265-73.
40. Paine MA, Scioscia M, Williams PJ, Gumaa K, Rodeck CH, Rademacher TW. Urinary inositol phosphoglycan P-type as a marker for prediction of preeclampsia and novel implications for the pathophysiology of this disorder. Hypertens Pregnancy 2010;29:375-84.
41. Myers JE, Tuytten R, Thomas G, Laroy W, Kas K, Vanpoucke G. Integrated proteomics pipeline yields novel biomarkers for predicting preeclampsia. Hypertension 2013;61:1281-8.
42. Gulaboglu M, Borekci B, Delibas I. Urine iodine levels in preeclamptic and normal pregnant women. Biol Trace Elem Res 2010;136:249-57.
43. Xiao J, Niu J, Ye X, Yu Q, Gu Y. Combined biomarkers evaluation for diagnosing kidney injury in preeclampsia. Hypertens Pregnancy 2013;32:1566-74.
44. Babu MS, Bobby Z, Habeebullah S. Increased inflammatory response and imbalance in blood and urinary oxidant-antioxidant status in South Indian women with gestational hypertension and preeclampsia. Clin Biochem 2012;45:835-8.
45. Dynon K, Heng S, Puryer M, Li Y, Walton K, Endo Y, et al. HtrA3 as an early marker for preeclampsia: specific monoclonal antibodies and sensitive high-throughput assays for serum screening. PLoS One 2012;7:e45956.
46. Son GH, Kwon JY, Lee S, Park J, Kim YJ, Yun B, et al. Comparison of serum and urinary nephrin levels between normal pregnancies and severe preeclampsia. Eur J Obstet Gynecol Reprod Biol 2013;166:139-44.
47. Moghbeli N, Srinivas SK, Bastek J, Lu Y, Putt ME, Cappola TP, et al. N-terminal pro-brain natriuretic peptide as a biomarker for hypertensive disorders of pregnancy. Am J Perinatol 2010;27:313-9.
48. Craici IM, Wagner SJ, Bailey KR, Fitz-Gibbon PD, Wood-Wentz CM, Turner ST, et al. Podocyturia predates proteinuria and clinical features of preeclampsia: longitudinal prospective study. Hypertension 2013;61:1289-96.
49. Hamad RR, Eriksson MJ, Berg E, Larsson A, Bremme K. Impaired endothelial function and elevated levels of pentraxin 3 in earlyonset preeclampsia. Acta Obstet Gynecol Scand 2012;91:50-6.
50. Dusse LM, Carvalho MG, Cooper AJ, Lwaleed BA. Plasma factor VII: A potential marker of pre-eclampsia. Thromb Res 2011;127:e15-9.
51. Hawkins TL, Roberts JM, Mangos GJ, Davis GK, Roberts LM, Brown MA. Plasma uric acid remains a marker of poor outcome in hypertensive pregnancy: A retrospective cohort study. Br J Obstet Gynaecol 2012;119:484-92.
52. Leanos-Miranda A, Marquez-Acosta J, Cardenas-Mondragon GM, Chinolla-Arellano ZL, Rivera-Leanos R, Bermejo-Huerta S, et al. Urinary prolactin as a reliable marker for preeclampsia, its severity, and the occurrence of adverse pregnancy outcomes. J Clin Endocrinol Metab 2008;93:2492-9.
53. Bellomo G, Venanzi S, Saronio P, Verdura C, Narducci PL. Prognostic significance of serum uric acid in women with gestational hypertension. Hypertension 2011;58:704-8.
54. Stampalija T, Chaiworapongsa T, Romero R, Chaemsaithong P, Korzeniewski SJ, Schwartz AG. Maternal plasma concentrations of sST2 and angiogenic/anti-angiogenic factors in preeclampsia. J Matern Fetal Neonatal Med 2013;26:1359-70.
55. D'Anna R, Baviera G, Giordano D, Todarello G, Corrado F, Buemi M. Second trimester neutrophil gelatinase-associated lipocalin as a potential prediagnostic marker of preeclampsia. Acta Obstet Gynecol Scand 2008;87:1370-3.
56. Sela S, Itin A, Natanson-Yaron S, Greenfield C, Goldman-Wohl D, Yagel S, et al. A novel human-specific soluble vascular endothelial growth factor receptor 1: cell-type-specific splicing and implications to vascular endothelial growth factor homeostasis and preeclampsia. Circ Res 2008;102:1566-74.
57. Rasanen J, Quinn MJ, Laurie A, Bean E, Roberts CT Jr, Nagalla SR, et al. Maternal serum glycosylated fibronectin as a point-ofcare biomarker for assessment of preeclampsia. Am J Obstet Gynecol 2015;212:82.e1-9.
58. Zhu L, Chen Y, Liu C, Deng H, Zhang N, Wang S, et al. Transthyretin as a novel candidate biomarker for preeclampsia. Exp Ther Med 2014;7:1332-6.
59. Santillan MK, Santillan DA, Scroggins SM, Min JY, Sandgren JA, Pearson NA, et al. Vasopressin in preeclampsia: A novel very early human pregnancy biomarker and clinically relevant mouse model. Hypertension 2014;64:852-9.
60. Buhimschi IA, Nayeri UA, Zhao G, Shook LL, Pensalfini A, Funai EF, et al. Protein misfolding, congophilia, oligomerization, and defective amyloid processing in preeclampsia. Sci Transl Med 2014;6:245ra92.
61. Wang T, Zhou R, Gao L, Wang Y, Song C, Gong Y. Elevation of urinary adipsin in preeclampsia: correlation with urine protein concentration and the potential use for a rapid diagnostic test. Hypertension 2014;64:846-51.
62. Patrelli TS, Dall'asta A, Gizzo S, Pedrazzi G, Piantelli G, Jasonni VM, et al. Calcium supplementation and prevention of preeclampsia: A meta-analysis. J Matern Fetal Neonatal Med 2012;25:2570-4.
63. Gizzo S, Noventa M, Di Gangi S, Saccardi C, Cosmi E, Nardelli GB, et al. Could molecular assessment of calcium metabolism be a useful tool to early screen patients at risk for pre-eclampsia complicated pregnancy? Proposal and rationale. Clin Chem Lab Med 2015;53:975-9.
64. Bowers GN Jr, Brassard C, Sena SF. Measurement of ionized calcium in serum with ion-selective electrodes: A mature technology that can meet the daily service needs. Clin Chem 1986;32:1437-47.
65. Bootman MD, Rietdorf K, Collins T, Walker S, Sanderson M. Ca2+-sensitive fluorescent dyes and intracellular Ca2+ imaging. Cold Spring Harb Protoc 2013;2013:83-99.
66. Hun X, Zhang Z. Preparation of a novel fluorescence nanosensor based on calcein-doped silica nanoparticles, and its application to the determination of calcium in blood serum. Microchimica Acta 2007;59:255-61.
67. Chappell LC, Duckworth S, Seed PT, Griffin M, Myers J, Mackillop L, et al. Diagnostic accuracy of placental growth factor in women with suspected preeclampsia: A prospective multicenter study. Circulation 2013;128:2121-31.
68. Coustan DR, Lowe LP, Metzger BE, Dyer AR. International Association of Diabetes and Pregnancy Study Groups. The Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study: paving the way for new diagnostic criteria for gestational diabetes mellitus. Am J Obstet Gynecol 2010;202:654.e1-6.
69. Navaratnam K, Alfirevic Z, Baker PN, Gluud C, Grüttner B, Kublickiene K, et al. A multi-centre phase IIa clinical study of predictive testing for preeclampsia: improved pregnancy outcomes via early detection (IMPROvED). BMC Pregnancy Childbirth 2013;13:226.
70. Kenny LC, Broadhurst DI, Dunn W, Brown M, North RA, McCowan L, et al. Robust early pregnancy prediction of later preeclampsia using metabolomic biomarkers. Hypertension 2010;56:741-9.